Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* COVID-19 infection, confirmed by polymerase chain reaction (PCR) test within 3 days from enrollment~* Only mild and moderate COVID-19 infected cases~* Able to provide informed consent~Exclusion Criteria:~* Unable to take oral medication~* Pregnant or breast feeding lady~* Patients with severe COVID symptoms or admission in ICU/HDU~* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) more than 5 upper limit of normal (ULN)~* On non-invasive positive pressure ventilation or mechanical ventilation at time of study entry~* Known hypersensitivity to Doxycycline or ivermectin or its components.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ivermectin and Doxycycline (Type: ACTIVE_COMPARATOR): Ivermactin 6 mg 2 tab stat, cap Doxycycline 100 mg 1 cap BD 5 days
- Placebo (Type: PLACEBO_COMPARATOR): Standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).